ReviewBlood advances2025
Venous thrombosis unchained: Pandora's box of noninflammatory mechanisms.
Review in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Mechanisms of Piezo1-Mediated Mechanotransduction in Thrombotic Diseases.International journal of molecular sciences · 2026Review
- Pharmacological Blockade of Hypoxia-Driven Autophagy: A Therapeutic Strategy to Limit Endothelial Activation and Thrombosis.ACS pharmacology & translational science · 2026Article
- Rethinking the selection of in vivo thrombosis models in the hybrid era.Nature cardiovascular research · 2026Article
- Cardiometabolic multimorbidity and short-term outcomes in pulmonary embolism: Findings from the CURES Registry-2.American journal of preventive cardiology · 2026Article
- Predicting deep vein thrombosis risk in patients with knee fractures: a nomogram-based study.Perioperative medicine (London, England) · 2026Article
- Circadian control of immune homeostasis in cardiovascular health and disease.Frontiers in immunology · 2026Review
- Association between triglyceride glucose- systemic immune inflammation index and deep venous thrombosis in fresh fracture patient: a real-world retrospective study.Frontiers in endocrinology · 2026Article
- Implementation outcomes of a VTE prevention and management system within the close-knit county medical alliance model.Frontiers in public health · 2026Article
- Atrial fibrillation and metabolic syndrome: an updated review of mechanisms, risk factors, and therapeutic strategies.Frontiers in cardiovascular medicine · 2026Review
- Metabolic syndrome, adipokines, coagulation factors, and venous thromboembolism: a two-step Mendelian randomization study.Diabetology & metabolic syndrome · 2025Article
- The molecular interplay between the gut microbiome and circadian rhythms: an integrated review.Frontiers in microbiology · 2025Review
- Explainable machine learning-based prediction of early and mid-term postoperative complications in adolescent tibial fractures.Frontiers in surgery · 2025Article
- The Triglyceride-glucose Index Predicts Short-Term Mortality in Critically Ill Patients With Cancer-Associated Thrombosis: A Retrospective Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractVenous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism, represents a complex pathological process extending far beyond inflammatory mechanisms. This review comprehensively examines the multifaceted noninflammatory mechanisms underlying thrombosis development, integrating insights from molecular, physiological, and systemic levels. Blood flow dynamics and endothelial function are known to be critical regulators of thrombus development. Platelets and microparticles play important roles beyond conventional inflammatory responses, actively contributing to thrombus formation through intricate molecular interactions. Metabolic syndrome and insulin resistance are associated with thrombotic risk, demonstrating the complex interplay between metabolic disorders and DVT. Certain genetic mutations also predispose individuals to venous thrombosis. Emerging research has discovered the essential role of previously underappreciated factors such as products of gut microbiota or endothelial glycocalyx modifications. Molecular regulators such as microRNAs and hormonal disbalance further illustrate the complex mechanisms of venous thrombosis. Interestingly, circadian rhythms exhibit certain influence on thrombotic potential, introducing chronobiology as an emerging variable affecting the risk of thrombosis. On the basis of these insights, future therapeutic strategies may include various interventions targeting or at least considering metabolic, molecular, and systemic noninflammatory factors. Potential approaches include personalized risk stratification, microbiome modulation, endothelial protection approaches, and chronotherapy-based therapeutic modalities, which would ensure more efficient and safe thrombosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.